CytomX’s Approach To Antibody-Drug Conjugates Earns Deal With Pfizer
This article was originally published in The Pink Sheet Daily
Executive Summary
The privately held California biotech calls its ADC technology Probody Drug Conjugates and claims it can create antibodies that will activate in a tumor’s micro-environment, while remaining dormant in healthy tissue. Pfizer is paying $25 million divided between upfront cash and preclinical milestones for a licensing deal around CytomX’s Probody Platform technology.
You may also be interested in...
AbbVie Partnership On CD71 Gives CytomX Big Upfront, Co-Promotion Potential
Deal to target antibody-drug conjugate concludes busy week in cancer partnering for AbbVie.
Third Rock Leads $30 Mil. Series B For CytomX
The startup, which develops antibodies designed to act selectively on diseased tissue, has two preclinical oncology programs.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.